Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial

Thomas Powles, Michael B. Atkins, Bernard Escudier, Robert J. Motzer, Brian I. Rini, Lawrence Fong, Richard W. Joseph, Sumanta K. Pal, Mario Sznol, John Hainsworth, Walter M. Stadler, Thomas E. Hutson, Alain Ravaud, Sergio Bracarda, Cristina Suarez, Toni K. Choueiri, James Reeves, Allen Cohn, Beiying Ding, Ning LengKenji Hashimoto, Mahrukh Huseni, Christina Schiff, David F. McDermott

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences